Iron and infection

Acta Clinica Belgica

Volumn 51, Issue 4, 1996, Pages 213-221

  Boelaert, J R ^a  

^a General Hospital St Jan   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; HYDROXYCHLOROQUINE;

HUMAN; INFECTION; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; REVIEW;

EID: 0029745308     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/22953337.1996.11718513     Document Type: Review

References (57)

1. Fondu P, Cantinieaux B. Infections and iron overload. Acta Clin Belg. 1986; 41: 1-9.
2. Weinberg ED. Iron and infection. Microbiol Rev. 1978; 42: 45-66.
3. Kochan I. The role of iron in bacterial infections, with special consideration of host-tubercle bacillus interaction. Curr Top Microbiol Immunol. 1973; 60: 1-30.
4. Brock J. Lactoferrin: a multifunctional immunoregulatory protein? Immunol Today. 1995; 16: 417-9.
5. Bellamy W, Takase M, Yamauachi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta. 1992; 1121: 130-6.
6. Bullen JJ, Spalding PB, Ward CG, Gutteridge JMC. Hemochromatosis, iron, and septicemia caused by Vibrio vulnificus. Arch Intern Med. 1991; 151: 1606-09.
7. Speeleveld E, Muyldermans L, Van Den Bruel A, Dhondt E, Gordts B, Van Landuyt HW. Prosthetic valve endocarditis due to Listeria monocytogenes. Acta Clin Belg. 1994: 49; 95-8.
8. Artis WA, Fountain JA, Delchez HK, Jones HE. A mechanism of suceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron bioavailability. Diabetes. 1982; 31: 1109-14.
9. Gupta KL, Radotra BP, Sakhuja V, Banarjee AK, Chugh KS. Mucormycosis in patients with renal failure. Renal Failure. 1990; 11: 195-9.
10. Lewis LL, Hawins HK, Edwards MS. Disseminated mucormycosis in an infant with methylmalonic aciduria. Pediatr Infect Dis J. 1990; 9: 851-4.
11. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992; 80: 1639-47.
12. Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today. 1995; 16: 495-9.
13. Byrd TF, Horwitz MA. Interferon-gamma activated human monocytes downregulate transferrin receptors and inhibit the intracellular mulplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest. 1988; 83: 1457-65.
14. Weinberg ED. Iron depletion: a defense against intracellular infection and neoplasia. Life Sciences. 1992; 50: 1289-97.
15. Albina JE. On the expression of nitric oxide synthase in human macrophages. Why no NO? J Leukoc Biol. 1998; 58: 643-9.
16. Weinberg ED. Acquisition of iron and other nutrients in vivo. In: Roth JA et al., eds. Virulence mechanisms of bacterial pathogens. Washington DC: American society for microbiology. 1995; 81-95.
17. Crichton RR. Inorganic biochemistry of iron metabolism. Ellis Horwood, ed. New York: Ellis Horwood series in inorganic chemistry. 1991.
18. Drechsel H, Metzger J, Freund S, Jung G, Boelaert JR, Winkelmann G. Rhizoferrin - a novel siderophore from the fungus Rhizopus microsporus var. rhizopodiformis. Biol Metals. 1991; 4: 238-43.
19. Brittenham GM. Development of iron-chelating agents for clinical use. Blood. 1992; 80: 569-74.
20. Robins-Browne RM, Prpic JK. Desferrioxamine and systemic yersiniosis. Lancet. 1983; 2: 1372.
21. Boelaert JR et al. The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients. J Infect Dis. 1987; 156: 384-6.
22. De Brouwer E, Van Landuyt HW, Gordts B, Boelaert JR. In vitro acquisition of iron from the iron-desferrioxamine complex by Aeromonas hydrophila. Clin Microbiol Infect. 1996, in press.
23. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991; 18: 660-7.
24. Boelaert JR, de Locht M, Schneider Y-J. The effect of deferoxamine on different zygomycetes. J Infect Dis. 1994; 169: 231-2.
25. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int. 1989; 36: 1061-68.
26. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993; 91: 1979-86.
27. Van den Saffele JK, Boelaert JR. Zygomycosis in HIV-positive patients: a review of the literature. Mycoses. 1996, in press.
28. Verpooten GA, D'Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant. 1992; 7: 931-8.
29. Boelaert JR, Van Cutsem J, de Locht M, Schneider Y-J, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Intern. 1994; 45:667-71.
30. 28a. Gordeuk VR et al. Iron overload in Africa: interaction between a gene and dietary iron content. N Engl J Med. 1992; 326: 95-100.
31. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant. 1990; 5: 130-4.
32. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. Nephron. 1993; 64: 95-100.
33. Gordeuk VR, Thuma P, Brittenham G et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med. 1992; 327: 1473-77.
34. Gordeuk VR et al. Transferrin saturation and recovery from coma in cerebral malaria. Blood. 1995; 85: 3297-301.
35. Raghu B, Raghupati S, Venkatesan P. Effect of iron on the growth and siderophore production of mycobacteria. Biochem Molec Biol Intern. 1993; 31: 341-8.
36. Murray MJ, Murray AB, Murray MB, Murray CJ. The adverse effect of iron repletion on the course of certain infections, Br Med J. 1978; 2: 1113-15.
37. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood. 1996; 87: 3470-76.
38. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management Infect Agents Dis. 1996; 5: 36-46.
39. Boelaert JR, Piette J, Weinberg GA, Sappey C, Weinberg ED. Iron and oxidative stress as a mechanism for the enhanced production of human immunodeficiency virus by alveolar macrophages from otherwise healthy cigarette smokers. J Infect Dis. 1996; 173: 1045-46.
40. Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, Piette J. Iron chelation decreases NF-κB and HIV-1 activation due to oxidative stress. AIDS Res Hum Retroviruses. 1995; 11: 1049-61.
41. Costagliola D, de Montalembert M. Lefrère J-J et al. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. Br J Haematol. 1994; 87: 849-52.
42. Van Asbeck BS, Verburgh HA, Van Oost BA, Marx JJM, Imhof HW, Verhoef J. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J. 1982; 284: 542-4.
43. Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol. 1992; 80: 235-41.
44. De Sousa M. Immune cell functions in iron overload. Clin Exp Immunol. 1989; 75: 1-6.
45. Mosmann TR, Coffmann RL. TH1 and TH2 cells: different pattern s of lymphokine secretions lead to different functional properties. Ann Rev Immunol. 1989; 7: 145-73.
46. Clerici M, Shearer GM. A TH1 ⇒TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993, 14: 107-11.
47. Gougeon ML, Olivier S, Garcia et al. Mise en évidence d'un processus d'engagement vers Ia mort cellulaire par apoptose dans les lymphocytes de patients infectés par le VIH. C R Acad Sci Paris, Sér III Sc Vie. 1991; 312: 529-40.
48. Clerici M, Sarin A, Coffman RL et al. Type 1/type 2 cytokine modulation of T cell programmed cell death as a model for HIV pathogenesis. Proc Natl Acad Sci USA. 1994; 91: 11811-75.
49. Weinberg ED, Weinberg GA. The role of iron in infection. Curr Opin Infect Dis. 1993; 8: 164-9.
50. Boelaert JR, de Locht M, Van Cutsem J. Desferrioxamine and microorganisms. Studies on in vitro growth and on experimental infections. A review. Rev Med Microbiol. 1993; 4: 171-5.
51. Cinatl J Jr, Cinatl J, Rabenau H, Gümbel HO, Kornhuber B, Doerr HW. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res. 1994; 25: 73-7.
52. Weinberg GA. Iron chelators as novel therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994; 38: 997-1003.
53. Newman SL, Gootee L, Brunner G, Deepe GS Jr. Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest. 1994; 93: 1422-29.
54. Sperber K et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Therap. 1995; 17: 622-36.
55. Rubin RB, Barton AL, Banner BF, Bonkovsky HL. Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis. 1995; 13: 223-38.
56. Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-alpha (Abstract). Hepatology. 1993; 18: 373.
57. Hayashi H et al. Improvement of serum amino-transferase levels after phlebotomy in patients with chronic hepatitis C and excess hepatic iron. Am J Gastroenterol. 1984; 89: 986-8.